ProKidney Announces Eight Abstracts for Kidney Week 2026

WINSTON-SALEM, N.C., Oct. 02, 2026 /CourierPR/ -- ProKidney Corp., a leading late clinical-stage cell therapy company focused on chronic kidney disease (CKD), today announced that the company will present eight abstracts, including one oral presentation, at the upcoming American Society of Nephrology’s (ASN) Kidney Week, which will be held from October 21-25, 2026, in Denver, Colorado. The abstracts cover a range of studies and analyses, including a Phase 2 pooled analysis that continues to indicate a strong safety profile and kidney function stabilization in patients with advanced CKD and type 2 diabetes mellitus.

The poster board number for this presentation is TH-PO1128.

The poster board number for this presentation is TH-PO1129.

ProKidney’s lead investigational product candidate, rilparencel (also known as REACT®), is a first-in-class, patented, proprietary autologous cell therapy with regenerative medicine advanced therapy designation that is being evaluated in the ongoing Phase 3 REGEN-006 (PROACT 1) study for its potential to preserve kidney function in patients with advanced CKD and type 2 diabetes. The company's lead product candidate, rilparencel, is a first-in-class, patented, proprietary autologous cell therapy with regenerative medicine advanced therapy designation that is being evaluated in the ongoing Phase 3 REGEN-006 (PROACT 1) study for its potential to preserve kidney function in patients with advanced CKD and type 2 diabetes.

ProKidney was founded in 2015 after a decade of research. The company's actual results may differ from its expectations, estimates, and projections and consequently, investors should not rely on these forward-looking statements as predictions of future events. The company's financial performance is expected to support operating plans into mid-2027, future performance, development and commercialization of products, if approved, the potential benefits and impact of the company's products, if approved, the potential regulatory approvals, the size and potential growth of current or future markets for the company's products, if approved, the advancement of the company's development programs into and through the clinic, and the expected timing for reporting data, the making of regulatory filings or achieving other milestones related to the company's product candidates, and the advancement and funding of the company's developmental programs, generally.